Cingulate Inc. (CING) is set to face a key FDA decision on May 31, 2026, for its once-daily ADHD candidate CTx-1301, currently under review via the 505(b)(2) regulatory pathway.
CTx-1301 is designed for the treatment of Attention-Deficit/Hyperactivity Disorder (ADHD) in both children and adults. The therapy uses Cingulate's Precision Timed Release (PTR) platform to deliver a multi-core formulation of dexmethylphenidate, an FDA-approved stimulant widely used in ADHD management. The PTR technology is engineered to provide consistent, all-day symptom control with a single morning dose—addressing limitations of existing extended-release stimulants, which often require multiple doses and may not maintain coverage throughout the active day.
For comments and feedback contact: editorial@rttnews.com
May 22, 2026 14:46 ET Minutes of the latest Fed policy session was the highlight of the week along with survey data on the U.S. housing market. In Europe, survey data signaled the trends in the euro area private sector. Further, consumer price inflation data from the U.K. was in focus. In Asia, various economic indicators from China drew attention to the health of the economy.